Wrap Technologies filed Q1 results after the close on May 13, and the headline numbers landed ahead of depressed expectations — yet the stock has barely moved, down 2% on the week to $1.43, with shorts starting to unwind from a still-elevated base.
Short sellers hold a meaningful grip here. Short interest is running at 11.6% of the free float — genuinely high for a micro-cap hardware name — but the direction of travel is clearly lower. From a peak near 12.5% of float in mid-April, borrowed shares have dropped about 4% over the past month and another 2% in the past week alone, falling to roughly 5.98 million shares. That slow bleed suggests some shorts are covering rather than adding pressure. The borrow market is in a normal zone — cost to borrow is around 6.9%, little changed on the week, and well off the brief spike above 10% that appeared briefly in early April during the tariff-driven market dislocation. Availability is not at a pinch point, and the ORTEX short score is elevated at 86.4 — sitting firmly in the top tier of the universe — but its near-term trajectory has been flat. The score has barely moved across ten daily readings, which tells you this is a stable bearish commitment rather than a fresh short-selling campaign.
Options positioning skews heavily toward calls. The put/call ratio is running at 0.12, only fractionally above its 20-day average of 0.11 and close to the lower end of its 52-week range. With the 52-week high PCR at 0.50, the current reading is essentially at the bullish extreme for this name — options traders are not buying downside protection. That is notable the day of an earnings print.
And the earnings print gave them something to work with. Q1 revenue came in at $1.1 million, up 45% year-on-year, with product sales — the company's core metric for BolaWrap field adoption — up 186%. Bookings reached $3.2 million in the quarter, well ahead of revenue recognised, and cash burn improved 59% to $1.2 million in operating activities. Management repeated their target of 100% revenue growth for full-year 2026, and CEO Scot Cohen said "conviction in that target has strengthened." New contract activity supports that: the company landed a DHS contract in the quarter and reported pre-orders for both drone and counter-drone systems, with early deployments in the UK, Panama, India and Europe. The company is explicitly positioning BolaWrap 150 as part of a broader non-lethal response platform that includes WrapVision, WrapTactics, and counter-UAS hardware.
The ownership table adds a layer of complication. Founder Elwood Norris — listed as an 8.1% holder — has been a persistent seller, moving roughly 336,000 shares in February alone at prices between $1.82 and $2.46. That supply kept a lid on the stock even as the business began to show early commercial momentum. Balancing that, Chairman and CEO Scot Cohen — the largest single holder at 15.4% of shares — bought 475,000 shares on February 2 at $2.00, alongside a $500,000 buy from board member John Shulman the same day. The insider picture is therefore split: the founder selling steadily into the market, and the current management team making concentrated open-market purchases at higher prices than where the stock trades today.
Analyst coverage is stale — the last recorded rating change was a downgrade to Neutral from Ladenburg Thalmann back in August 2022, and all available analyst data predates 2023 by more than three years. It carries no weight in the current setup. The analyst return-potential reading of 74.8% from the screening data may reflect that stale target rather than current Street views, and investors should treat it accordingly.
What to watch: the gap between $3.2 million in Q1 bookings and $1.1 million in revenue recognised is the central tension for Q2 — whether those bookings convert into reported sales will determine whether management's 100% full-year growth target holds.
See the live data behind this article on ORTEX.
Open WRAP on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
